Dry eye disease (DED) represents one the most frequent eye disorders encountered in clinical practice, with a reported prevalence ranging between 5% and 50% in the adult population.

Tear supplementation represents the mainstay of current DED management; in the last few years, there has been a progressive shift towards complex multi-action combined formulas targeting and disrupting different key mechanisms within the DED vicious cycle.

Trimix eye drop is a combination of viscosity-enhancing hyaluronic acid, trehalose, and cationic liposomes comprising stearylamine and phospholipids, which has shown promising results in both animal and ex vivo models of DED.

Trimix eye drops administered three times daily for 2 months led to a significant improvement in noninvasive breakup time (NIBUT), tear meniscus height (TMH), and lipid layer thickness (LLT) in patients with mild to moderate DED.

Trimix eye drops significantly also improved ocular discomfort symptoms while showing a good tolerability profile.